ArticleWorld journal of gastroenterology2014
Differential control of growth, apoptotic activity and gene expression in human colon cancer cells by extracts derived from medicinal herbs, Rhazya stricta and Zingiber officinale and their combination.
Article in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 27 citations in OpenAlex.
- Anticancer Properties of Garlic and Ginger Extract in Colon Cancer Cell Line.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- Pharmacological activity and clinical application analysis of traditional Chinese medicine ginger from the perspective of one source and multiple substances.Chinese medicine · 2024Review
- Mechanisms of Chemopreventive and Therapeutic Proprieties of Ginger Extracts in Cancer.International journal of molecular sciences · 2021Review
- Antioxidant and immune responses of broiler chickens supplemented withVeterinary world · 2021Article
- Integration of medicinal plants into the traditional system of medicine for the treatment of cancer in Sokoto State, Nigeria.Heliyon · 2020Article
- ITS2: An Ideal DNA Barcode for the Arid Medicinal Plant Rhazya Stricta.Pharmaceutical medicine · 2019Article
- Modulation of Multiple Signaling Pathways of the Plant-Derived Natural Products in Cancer.Frontiers in oncology · 2019Review
- Saudi anti-human cancer plants database (SACPD): A collection of plants with anti-human cancer activities.Oncology reviews · 2018Article
- Crude Flavonoid Extract of Medicinal HerbOncology research · 2017Article
- Cheminformatics studies to analyze the therapeutic potential of phytochemicals fromChemistry Central journal · 2017Article
- Gene Expression Profiling to Delineate the Anticancer Potential of a New Alkaloid Isopicrinine FromIntegrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo investigate the effects of extracts from Rhazya stricta (R. stricta) and Zingiber officinale (Z. officinale) on human colorectal cancer cells.
methodsHuman colorectal cancer cells (HCT116) were subjected to increasing doses of crude alkaloid extracts from R. stricta (CAERS) and crude flavonoid extracts from Z. officinale (CFEZO). Cells were then harvested after 24, 48 or 72 h and cell viability was examined by trypan blue exclusion dye test; clonogenicity and soft agar colony-forming assays were also carried out. Nuclear stain (Hoechst 33342), acridine orange/ethidium bromide double staining, agarose gel electrophoresis and comet assays were performed to assess pro-apoptotic potentiality of the extracts. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR), using gene-specific primers and Western blot analyses were performed to assess the impact of CAERS and CFEZO on the expression levels of key regulatory proteins in HCT116 cells.
resultsTreatment with a combination of CAERS and CFEZO synergistically suppressed the proliferation, colony formation and anchorage-independent growth of HCT116 cells. Calculated IC50, after 24, 48 and 72 h, were 70, 90 and 130 μg/mL for CAERS, 65, 85 and 120 μg/mL for CFEZO and 20, 25 and 45 μg/mL for both agents, respectively. CAERS- and CFEZO-treated cells exhibited morphologic and biochemical features of apoptotic cell death. The induction of apoptosis was associated with the release of mitochondrial cytochrome c, an increase in the Bax/Bcl-2 ratio, activation of caspases 3 and 9 and cleavage of poly ADP-ribose polymerase. CAERS and CFEZO treatments downregulated expression levels of anti-apoptotic proteins including Bcl-2, Bcl-X, Mcl-1, survivin and XIAP, and upregulated expression levels of proapoptotic proteins such as Bad and Noxa. CAERS and CFEZO treatments elevated expression levels of the oncosuppressor proteins, p53, p21 and p27, and reduced levels of the oncoproteins, cyclin D1, cyclin/cyclin-dependent kinase-4 and c-Myc.
conclusionThese data suggest that a combination of CAERS and CFEZO is a promising treatment for the prevention of colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.